Moxifloxacin Based Triple Therapy as Alternative to Standard Therapy in Helicobacter Pylori Eradication

Mohammed, Hamdy; Aya, Makoto

doi:10.2174/2211352518999200925154501

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the usual triple therapy had a 75.2% H. pylori eradication rate, and other studies have reported rates between 61 and 77%. [27][28][29][30] In contrast to other studies, certain investigations 31,32 showed greater rates (85-94%). Therefore, it makes sense to assume that variations in eradication rates are correlated with the degree of adherence and/or the local susceptibility pattern of H. pylori in the investigated areas.…”

Section: Discussionmentioning

confidence: 66%

Association Between Vitamin D Receptor Polymorphism and the Response to Helicobacter Pylori Treatment

Abo-Amer¹,

Mohamed²,

Elhoseeny³

et al. 2023

IDR

View full text Add to dashboard Cite

Background & Aims This research aimed to determine how variations in the vitamin D receptor gene affected the response of H. pylori infections to eradication therapy. Patients and Methods On 105 adult H. Pylori -positive patients, a prospective cohort study was carried out. PCR was used to genotype all patients’ VDR gene polymorphisms. The patients in the study received standard triple eradication medication (clarithromycin 500 mg, amoxicillin 1000 mg, and omeprazole 20 mg) twice daily for 14 days. A stool test for H. pylori Ag was conducted 4 weeks following the end of treatment. Results In our study, the usual triple therapy’s H. pylori eradication rate was 75.2%. The successful eradication of H. pylori and VDR rs 2228570 gene polymorphisms was more prevalent in CT gene polymorphism (64.6%) compared to non-responders (19.2%), while treatment failure was more prevalent in CC gene polymorphism (73.1% in non-responders compared to responders 24.1%), which is statistically significant. In regards to the eradication of H. pylori and VDR rs7975232 gene polymorphisms, the success of eradication was more prevalent in AC gene polymorphism (54.4%) vs non-responders (30.4%), while all patients (14) with gene AA (17.7%) are responders to standard treatment, while the failure of treatment was more prevalent in CC gene polymorphism (69.2% in non-responder vs 27.8% in responders) which is statistically significant. Our findings demonstrated a strong correlation between patients’ responses to H. pylori treatment and polymorphisms in the VDR gene (ApaI and TaqI) (P 0.05). Conclusion As far as we are aware, this is the first study to identify a potential link between the FokI and Apal VDR polymorphism and treatment response in H pylori -positive patients. To evaluate the findings, more research with larger number of patients and different population is required.

show abstract

Section: Discussionmentioning

confidence: 66%

Association Between Vitamin D Receptor Polymorphism and the Response to Helicobacter Pylori Treatment

Abo-Amer¹,

Mohamed²,

Elhoseeny³

et al. 2023

IDR

View full text Add to dashboard Cite

show abstract

“…Ahmed et al conducted a comparative study between triple-therapy regimens utilizing moxifloxacin and clarithromycin. The study findings suggest that the rates of eradication were relatively high in the moxifloxacin-based therapy [20]. Similarly, Akpinar et al reported that moxifloxacin-based triple therapy was superior to bismuth-based quadruple therapy for the first-line treatment of Helicobacter pylori infection [15].…”

Section: Discussionmentioning

confidence: 75%

The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials

Khadim,

Naeem,

Alam

et al. 2023

Arch Med Sci Civil Dis

View full text Add to dashboard Cite

IntroductionThe challenge of eradicating Helicobacter pylori through antibiotic treatment is still a significant concern due to the existence of antibiotic resistance. This study aimed to evaluate and compare the efficacy of sequential therapy based on levofloxacin versus triple therapy based on moxifloxacin in treating H. pylori infection in patients receiving first-line treatment.Material and methodsA total of 162 patients who were examined positive for H. pylori were randomly assigned to either of 2 groups to receive the following: (a) levofloxacin 500mg BID, amoxicillin 1 g BID, and omeprazole 20 mg BID for the first 5 days, followed by levofloxacin 500 mg BID, tinidazole 500 mg BID, and omeprazole 20 mg BID (LAO-LTO group); or (b) moxifloxacin 400 mg OD, amoxicillin 1 g BID, and omeprazole 20 mg BID (MAO group) for 10 days.ResultsThe eradication rate of H. pylori in the LAO-LTO group was 58.4% (45/77) and 76.3% (45/59), and in the MAO group it was 81.2% (69/85) and 92% (69/75), respectively, in ITT and PP analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than those of levofloxacin-based regimens (p < 0.001). The overall incidence of side effects and patient compliance was significantly lower in the moxifloxacin group (p < 0.005) than in the levofloxacin group.ConclusionsMoxifloxacin-based triple therapy could be a significantly more effective first-line eradication treatment as compared to levofloxacin-based sequential therapy for H. pylori infection in Pakistan.

show abstract

Comparison of Therapeutic Outcomes: Two Triple-Therapy Approaches for H. pylori Eradication in Gastric Ulcer Disease

Amil,

Sajjad,

Khan

et al. 2024

PJHS

View full text Add to dashboard Cite

Gastric ulcer is a prevalent digestive disease, primarily caused by Helicobacter pylori infection. H. pylori infection poses a substantial challenge for medical practitioners due to increased antibiotic resistance. Objectives: To compare the efficacy of a 14-days clarithromycin-based triple therapy (TRT) with a moxifloxacin-based TRT for eradicating Helicobacter pylori in gastric ulcer disease. Methods: A quasi experimental study was conducted with 294 positive H. pylori patients divided into two groups. Group A was given standard triple therapy while Group B received moxifloxacin-based triple therapy. Data collection commenced after obtaining IRB approval and informed consent from all participants. Descriptive statistics was used to calculate frequency and percentages. Differences between the two groups were compared using the fisher exact analysis at a significance level, p-value < 0.05. Results: In the group with standard triple therapy (TRT), the eradication rates of H. pylori were reported as 67.3 % intention-to-treat (ITT) and 76.1% per-protocol (PP) analysis. In contrast, in the moxifloxacin-based triple therapy (MAO) group, the eradication rates were 86.3% ITT and 92.7% PP analysis. The eradication rates with moxifloxacin-containing triple therapy were statistically significant than standard TRT (p = 0.001). Furthermore, few side effects were evident in the moxifloxacin TRT group (p < 0.001) compared to the standard TRT group. Conclusions: In Pakistan, moxifloxacin-containing triple therapy may offer a notably superior treatment option for eradicating H. pylori infection compared to standard triple therapy.

show abstract

Moxifloxacin Based Triple Therapy as Alternative to Standard Therapy in Helicobacter Pylori Eradication

Cited by 3 publications

References 0 publications

Association Between Vitamin D Receptor Polymorphism and the Response to Helicobacter Pylori Treatment

Association Between Vitamin D Receptor Polymorphism and the Response to Helicobacter Pylori Treatment

The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials

Comparison of Therapeutic Outcomes: Two Triple-Therapy Approaches for H. pylori Eradication in Gastric Ulcer Disease

Contact Info

Product

Resources

About